FDA Approves First Drug for Primary Membranous Nephropathy

The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva) as the first drug specifically for adults with primary membranous nephropathy (PMN) at risk of disease progression. This approval is based on the Phase 3 MAJESTY trial, which demonstrated significant rates of complete remission.